EUVIMEDEUVIMED entdecken
Multizentrische Studie

Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National Analysis

Kate Solpari, Zane Gouda, Allysa Saggese, Adam Buckholz, Reem Z Sharaiha, Sonal Kumar, Tatyana Kushner iD

Liver International · 2026-04 · 46 (4)

DOI: 10.1111/liv.70580 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 13.03.2026. Verfasst von Kate Solpari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Practice Patterns, Physicians'. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resmetirom received FDA approval in March 2024 as the first therapy for noncirrhotic MASH with moderate‐to‐advanced fibrosis. This retrospective cohort study used the TriNetX Research Network to assess early prescribing patterns among 3712 patients across 44 healthcare organisations. The mean age was 57.6 years, 57% were female, and the mean BMI was 33.9 kg/m 2 . The cohort was predominantly White (73.8%), with representation from Hispanic/Latino (11.7%) and Asian (8.1%) populations. MASLD and MASH diagnoses were documented in 72% and 56% of patients, while 15% carried cirrhosis codes. Common comorbidities included dyslipidaemia (55%), hypertension (52%) and type 2 diabetes (41%). GLP‐1 receptor agonists were commonly prescribed, with semaglutide ( n = 1124), tirzepatide ( n = 842), dulaglutide ( n = 391) and liraglutide ( n = 203) representing the most frequently used agents. Among 19 643 treatment‐eligible patients (1057 treated and 18 586 untreated), 5.4% received resmetirom. Treated patients were more frequently Asian or Hispanic and more likely to be prescribed GLP‐1 receptor agonists, statins, metformin or ARBs (all p < 0.01). Early prescribing demonstrates preferential use among individuals with higher metabolic burden but reveals potential miscoding or off‐label use and significant underutilization among eligible populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsPractice Patterns, Physicians'AgedFemaleHumansMaleMiddle AgedDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsLiraglutideRetrospective StudiesSemaglutideTirzepatideUnited StatesGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Substanzen

dulaglutideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLiraglutideSemaglutideTirzepatideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA.
  • Division of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA.

ORCID-Profile: Tatyana Kushner

Zitieren

APA

Solpari, K., Gouda, Z., Saggese, A., Buckholz, A., Sharaiha, R. Z., Kumar, S., & Kushner, T. (2026). Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National Analysis. Liver International, 46(4). https://doi.org/10.1111/liv.70580

Vancouver

Solpari K, Gouda Z, Saggese A, Buckholz A, Sharaiha RZ, Kumar S, et al. Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National Analysis. Liver International. 2026;46(4). doi:10.1111/liv.70580

BibTeX
@article{Solpari2026,
  author = {Solpari, Kate and Gouda, Zane and Saggese, Allysa and Buckholz, Adam and Sharaiha, Reem Z and Kumar, Sonal and Kushner, Tatyana},
  title = {Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National Analysis},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {4},
  doi = {10.1111/liv.70580}
}
Kostenlos starten →